Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024
01 août 2024 11h20 HE
|
Ultimovacs ASA
Oslo, August 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that an update from the Phase II...
Ultimovacs ASA announces revised terms of the employee share option program
24 juin 2024 15h00 HE
|
Ultimovacs ASA
Oslo, June 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, announces revised terms of the employee share option...
Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab
11 juin 2024 01h00 HE
|
Ultimovacs ASA
All patients in the trial who were alive at 3 years remain alive at 4 years (69.5%) with a minimum follow-up period of 4 years (median 53.0 months)The expected next key milestone for UV1 is the...
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
01 juin 2024 08h15 HE
|
Ultimovacs ASA
NON-REGULATORY PRESS RELEASE Oslo, June 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that...
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update
07 mai 2024 01h00 HE
|
Ultimovacs ASA
Ultimovacs remains committed to continuing the clinical development strategy and exploring multiple pathways for UV1.The negative INITIUM results have had important consequences for the Company....
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
30 avr. 2024 01h00 HE
|
Ultimovacs ASA
Oslo, April 30, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its first...
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24 avr. 2024 10h15 HE
|
Ultimovacs ASA
NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer...
Ultimovacs ASA – Annual General Meeting held on April 18, 2024
18 avr. 2024 08h42 HE
|
Ultimovacs ASA
Oslo, April 18, 2023: Ultimovacs ASA held its annual general meeting today April 18, 2024. All the matters on the agenda were approved. The following board members were re-elected for a period of one...
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program
16 avr. 2024 16h10 HE
|
Ultimovacs ASA
Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to...
Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
15 avr. 2024 01h00 HE
|
Ultimovacs ASA
Oslo, April 15, 2024: In connection with the Annual General Meeting of Ultimovacs ASA to be held on April 18, 2024, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy based...